Botox vs. Jeuveau: How “Newtox” Compares to the Original (2026 Guide)

If you are weighing Botox against Jeuveau — the FDA-approved cosmetic neuromodulator that earned the “Newtox” nickname when it launched in 2019 — the honest headline is that these two products are the most clinically similar pair in the entire FDA-approved category. Same accessory-protein complex size. Same 1:1 dosing. Same onset window. Same duration window. The meaningful differences come down to price, branding, and where you can get each product.

This guide walks through every meaningful difference between Botox and Jeuveau based on the current FDA labels and the EV-001/EV-002 phase-3 trial data, plus what to expect at a competent clinic. Because Jeuveau is not part of our menu, this guide is written to help you choose between the two on the merits — and to help you understand the Naya-carried alternative if Jeuveau is hard to access in your area.

What Botox and Jeuveau Actually Are

Both are purified type A botulinum toxin. Both block acetylcholine release at the neuromuscular junction, which silences the targeted facial muscle and smooths the overlying dynamic wrinkle.

Of all the FDA-approved cosmetic neuromodulators, these two have the most chemically similar formulations:

• Botox (onabotulinumtoxinA) — made by Allergan Aesthetics (an AbbVie company), FDA-approved for cosmetic glabellar lines in 2002 and for forehead lines and crow’s feet in subsequent years. Formulated with a roughly 900 kDa accessory-protein complex and human serum albumin.
• Jeuveau (prabotulinumtoxinA-xvfs) — made by Evolus, FDA-approved for cosmetic glabellar lines in February 2019. Also formulated with a roughly 900 kDa accessory-protein complex (Evolus markets this as their “Hi-Pure” technology) and human serum albumin. Notably, Jeuveau is FDA-approved exclusively for aesthetic indications — it is not approved for therapeutic uses like migraine or hyperhidrosis, unlike Botox.

The aesthetics-only positioning matters more for Evolus’s marketing than for patients in the chair: when you are getting glabellar lines treated, what is in the syringe is functionally a Botox analog at the molecular level.

Onset: When Will You See Results?

Jeuveau is modestly faster to onset than Botox on average, though peak effect lands in the same window.

• Jeuveau onset: Most patients see softening at 2–3 days, with peak effect at roughly 10–14 days.
• Botox onset: Most patients see softening at 3–7 days, with peak effect also around 10–14 days.

For routine maintenance treatments, the onset difference washes out. For a same-week event, Jeuveau’s faster median onset can be a small advantage, similar to Dysport and Letybo.

Duration: How Long Will Results Last?

Duration is essentially the same between the two.

• Botox: Typical duration is 3–4 months for glabellar lines. The FDA label specifies that re-treatment should not be more frequent than every 3 months.
• Jeuveau: Typical duration is also 3–4 months. Evolus’s EV-001 and EV-002 phase-3 trials reported duration profiles comparable to onabotulinumtoxinA.

If duration is the single most important factor in your decision, neither of these is the right answer — the longer-acting FDA-approved option to discuss with your injector is Daxxify, which is studied at a median of approximately 6 months.

Dosing: The 1:1 Conversion

Per the FDA labels:

• Botox for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).
• Jeuveau for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).

The conversion is 1:1. Clinically, an injector trained on Botox dosing for a given area can use the same per-area unit counts with Jeuveau. The FDA labels still warn that units between branded products are not formally interchangeable, so a competent injector documents which product was used at what dose, but the practical math does not require relearning.

This is the same 1:1 simplicity you get with Letybo, and it is part of why both products have been relatively easy entries for clinics that already have Botox-fluent injectors on staff.

Diffusion and Precision

Both Botox and Jeuveau have tight, precise diffusion profiles. Neither product is known for spreading meaningfully beyond the injection point at standard cosmetic doses. In practical terms, Jeuveau behaves like Botox — appropriate for the same focal targets (crow’s feet, lip flips, masseters) where you do not want unintended spread to neighboring muscle groups.

The chemical similarity between the two products extends to their diffusion behavior. Choose between them on cost, access, and provider familiarity, not on diffusion mythology.

Cost: What You Will Actually Pay in 2026

National 2026 averages, with the caveat that prices vary by city and clinic experience:

• Botox: roughly $12–$20 per unit, with most clinics in the $14–$16 range. A standard glabellar treatment (20 units) lands around $280–$320.
• Jeuveau: roughly $8–$12 per unit. A standard glabellar treatment (20 units) lands around $200–$280.

Because the dosing is 1:1, the per-unit price advantage flows directly to per-treatment cost. The typical gap is in the $60–$100 range per glabellar treatment — meaningful if you are coming in 3–4 times per year and treating multiple areas, but small enough that you should not switch from a provider you trust solely to chase Jeuveau pricing.

One thing to watch with any lower-priced product: per-unit pricing should be transparent, and the unit count for your treatment area should match the FDA-label-suggested ranges. Vague “per-area” pricing can hide undertreatment regardless of the brand.

Side Effects and Safety

The side effect profiles of Botox and Jeuveau are very similar, as is the case for all type A botulinum toxins. In the EV-001 and EV-002 trials and in post-marketing data, the most common adverse events for Jeuveau were:

• Headache (3–9%)
• Injection-site reactions — bruising, redness, mild swelling (1–5%)
• Eyelid drooping (ptosis), uncommon in experienced hands
• Asymmetric brow position, typically correctable at a 2-week touch-up

Both products carry the same FDA boxed warning about the theoretical possibility of distant toxin spread. In cosmetic facial doses, this has not been a clinically meaningful concern across millions of treatments. The single most important safety variable remains the injector — choose a board-certified provider with extensive volume experience in whichever product they are using.

Who Is the Ideal Candidate for Each?

Botox may be the better fit if:

• You want the longest established US cosmetic track record
• You have used Botox successfully in the past and have no specific reason to switch
• Your provider has substantially more volume experience with Botox than with Jeuveau
• You want a product that is also FDA-approved for non-cosmetic uses, in case you ever need it (chronic migraine, hyperhidrosis, etc.)

Jeuveau may be the better fit if:

• Cost is the primary driver and you have access to a provider with volume experience in Jeuveau
• You like the idea of a Botox-equivalent dosing experience without retraining your expectations
• You are an aesthetics-only patient and the brand’s aesthetics-only positioning appeals to you
• You want a faster median onset (this is a small advantage shared by Jeuveau, Dysport, and Letybo)

Can You Switch Between Botox and Jeuveau?

Yes. Because the two products are dosed 1:1 and share very similar formulations, switching between them is among the simpler product transitions in the category. A few practical notes:

• Always tell your new injector which product you previously had, the dose, and roughly when it was administered. Even with 1:1 dosing, documentation matters.
• You cannot combine the two products in the same treatment area in the same session.
• Most patients describe no perceptible difference when switching from Botox to Jeuveau or vice versa between sessions.
• Switching does not reduce the very small theoretical risk of antibody formation against either toxin.